Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1443571
This article is part of the Research Topic Signaling Transduction of Innate Immunity and Regulation Mechanisms in the Tumor Immune Microenvironment View all 3 articles

Adeno-associated virus mediated artificial circular RNA for triggering cancer immunotherapy to treat prostate cancer

Provisionally accepted
Chujin Ye Chujin Ye *Yanlin Tang Yanlin Tang Jiayi Zeng Jiayi Zeng Chujin Ye Chujin Ye Jiumin Liu Jiumin Liu Haibiao Xie Haibiao Xie
  • Guangdong Provincial People's Hospital, Guangzhou, China

The final, formatted version of the article will be published soon.

    Specifically regulating endogenous molecules is a potential molecular therapeutic strategy.Naturally occurring circular RNAs (circRNAs) are structurally stable and have been proved to serve as highly efficient miR-sponges and protein-sponges in cancer cells. We chemically synthesized circRNA (ScircRNA) in vitro to achieve therapeutic dysfunction by targeting specific miRNAs. RNase R and fetal bovine serum were used to evaluate the stability of ScircRNAs. In prostate cancer cell lines, the competitive inhibition of the ScircRNA on miR-375 and miR-21 activity was evaluated using luciferase report gene, cell proliferation, and apoptosis assays. We found that ScircRNAs were more resistant to nuclease digestion and more effective inhibiting target miRNAs than linear RNA sponges. The ScircRNAs inhibited malignant phenotype of prostate cancer by specifically inhibiting the activity of miR-21 and miR-375. In addition, we used the ScircRNA inhibiting CDK5 expression to trigger T-cell mediated cancer immunotherapy for treating prostate cancer in vivo. In conclusion, the ScircRNAs possessed the advantages of stable structure and simple construction, and can specifically inhibit the function of target miRNAs, which has a potential therapeutic application prospect in prostate cancer.

    Keywords: prostate cancer, miRNA, circRNA, cancer immunotherapy, Synthetic Biology

    Received: 04 Jun 2024; Accepted: 07 Jan 2025.

    Copyright: © 2025 Ye, Tang, Zeng, Ye, Liu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chujin Ye, Guangdong Provincial People's Hospital, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.